The efficacy and safety of low-molecular-weight heparins (LMWHs) versus unfractionated heparin (UFH) has been demonstrated for the prevention of venous thromboembolism (VTE) after acute ischemic stroke. Few data exist regarding the economic impact of LMWHs versus UFH in this population. A decision-analytic model was constructed using clinical information from the Prevention of VTE after Acute Ischemic stroke with LMWH Enoxaparin (PREVAIL) study, and drug costs and mean Centers for Medicare & Medicaid Services event costs. When considering the total cost of events and drugs, enoxaparin was associated with cost-savings of $895 per patient compared with UFH ($2018 vs $2913). Findings were retained within the univariate and multivariate analyses. From a payer perspective, enoxaparin was cost-effective compared with UFH in patients with acute ischemic stroke. The difference was driven by the lower clinical event rates with enoxaparin. Use of enoxaparin may help to reduce the clinical and economic burden of VTE.
Kelly J., Rudd A., Lewis R., Hunt BJVenous thromboembolism after acute stroke. Stroke. 2001;32(1):262-267.
2.
McCarthy ST, Turner JJ, Robertson D., Hawkey CJ, Macey DJLow-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet. 1977;2(8042):800-801.
3.
McCarthy ST, Turner J.Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing. 1986;15(2):84-88.
4.
Kelly J., Rudd A., Lewis RR, Coshall C., Moody A., Hunt BJVenous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke. 2004;35(10):2320-2325.
Sherman DG, Albers GW, Bladin C., et al; PREVAIL Investigators. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison . Lancet. 2007;369(9570):1347-1355.
7.
Hillbom M., Erilä T., Sotaniemi K., Tatlisumak T., Sarna S., Kaste M.Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand . 2002;106(2):84-92.
8.
Sandercock PA , Counsell C., Tseng MCLow-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(3): CD000119.
9.
Diener HC, Ringelstein EB, von Kummer R., et al; PROTECT Trial Group. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke. 2006 ;37(1): 139-144.
10.
Shorr AF, Jackson WL, Sherner JH, Moores LKDifferences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis. Chest. 2008;133(6):149-55.
11.
Geerts WH, Bergqvist D., Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl): 381S-453S.
12.
Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G.Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest. 2002;122(1):108-114.
13.
Spyropoulos AC, Lin J.Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13(6):475-486.
14.
MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J.Economic burden of deep-vein thrombosis, pulmonary embolism and post-thrombotic syndrome. Am J Health Syst Pharm . 2006;63(20 suppl 6):S5-S15.
15.
Deitelzweig SB, Becker R., Lin J., Benner J.Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thromb Haemost. 2008; 100(5):810-820.
16.
McGarry LJ, Thompson D., Weinstein MC, Goldhaber SZCost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care. 2004;10(9):632-642.
17.
Pineo GF, Albers GW, Baldin C., et al. Enoxaparin versus unfractionated heparin for venous thromboembolism (VTE) prophylaxis in acute ischemic stroke patients. J Thromb Haemost. 2007;5(suppl 2):P-T-669.
18.
Burleigh E., Wang C., Foster D., et al. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. Am J Health Syst Pharm. 2006 ;63(20 Suppl 6):S23-S29.
19.
de Lissovoy G. , Subedi P.Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective . Am J Manag Care. 2002; 8(12):1082-1088.
20.
Offord R., Lloyd AC, Anderson P., Bearne A.Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharm World Sci. 2004;26(4): 214-220.
21.
Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800.
22.
Amin A., Stemkowski S., Lin J., Yang G.Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost. 2007;5(8):1610-1616.
23.
Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
24.
Tapson VF, Decousus H., Pini M., et al; IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest . 2007;132(3): 936-945.
